AxioMx, a biotechnology firm, has raised about $2 million in venture debt, according to a new filing by the company with the Securities and Exchange Commission. Four separate investors participated in the offering.

AxioMx is applying knowledge gained from the past 15 years of human genome sequencing to produce highly specific recombinant antibodies against the human proteome. The existing antibody development paradigm is too slow and does not always result in consistent, renewable, and quality antibodies. Through proprietary advances in traditional phage display antibody library design, phage display screening and affinity maturation technologies, we rapidly generate antibodies at the required binding and specificity criteria. At AxioMx, we believe our platform will lead to the wide adoption of recombinant antibody use in research and diagnostic applications.